Clinical trials: Constipation Chronic Idiopathic
Constipation Chronic Idiopathic
MowOot and Trans-anal Irrigation fOr coNstipation
This prospective, open-labelled, longitudinal, controlled study aims to evaluate the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for adults with refractory chronic constipation who are awaiting trans-anal…
- Trial name
- MOTION (NCT06833684)
- Testing
- ICE Treatment, TAI Standard-of-Care Treatment
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- usMIMA S.L.
Chronic Idiopathic Constipation
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.
- Trial name
- NCT02481947
- Testing
- BLI400 Laxative, Lubiprostone
- Where
- 50 sites in United States
- Volunteers
- 459 people
- Sponsor
- Braintree Laboratories
Constipation and Dyspepsia
The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia
- Trial name
- NCT00277550
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novartis
Constipation
Prucalopride in Patients With Chronic Idiopathic Constipation
The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic idiopathic constipation. Hypothesis: Prucalopride given at a dose of 1 mg o.d.
- Trial name
- NCT00575614
- Testing
- prucalopride
- Volunteers
- 87 people
- Sponsor
- Movetis
Chronic Idiopathic Constipation
This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants
This study aims to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties and food effect of IN-114199 in healthy participants
- Trial name
- NCT06736912
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Constipation Chronic Idiopathic
Tolerability Study of Panosyl Isomaltooligosaccharides (PIMO), in Subjects With Chronic Idiopathic Constipation (CIC)
This is a randomized, double blind, placebo controlled trial to evaluate the tolerability of MHS 1031. Tolerability will be assessed using the change in complete spontaneous bowel movements (CSBM), PRO questionnaires, concomitant…
- Trial name
- NCT05129618
- Testing
- MHS 1031
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Microbiome Health Sciences
Functional Constipation (FC)
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
The goal of this clinical trial is to learn if plecanatide can treat functional constipation in children and adolescents aged 6 to less than 18 years.
- Trial name
- Trulance (NCT07723924)
- Testing
- plecanatide
- Where
- 29 sites in United States
- Volunteers
- 180 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation, Chronic Idiopathic Constipation
BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
The objective of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus placebo in constipated adults.
- Conditions
- Constipation, Chronic Idiopathic Constipation, CIC
- Trial name
- NCT02819297
- Testing
- BLI400 Laxative
- Where
- 51 sites in United States
- Volunteers
- 1,020 people
- Sponsor
- Braintree Laboratories
Chronic Idiopathic Constipation
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic…
- Trial name
- NCT01429987
- Testing
- plecanatide
- Where
- 121 sites in United States
- Volunteers
- 951 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The CIC3 Study)
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
- Trial name
- NCT01982240
- Testing
- Plecanatide, Bisacodyl
- Where
- 189 sites in United States, Canada
- Volunteers
- 1,394 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT01919697
- Testing
- Plecanatide
- Where
- 220 sites in United States, Canada
- Volunteers
- 2,370 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation
The objective of this study is to evaluate the clinical equivalence and safety of the test formulation of Lubiprostone 24 mcg capsules manufactured by Dr Reddy's Laboratories Ltd compared to the marketed formulation AMITIZA® …
- Trial name
- NCT01674530
- Testing
- Lubiprostone
- Where
- 93 sites in United States
- Volunteers
- 909 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
The study is a prospective, randomized, multicenter, adaptive design, double blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs.
- Trial name
- Vibrant (NCT03879239)
- Testing
- Vibrating capsule
- Where
- 8 sites in United States
- Volunteers
- 349 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation.
- Trial name
- NCT01993875
- Testing
- Lubiprostone
- Where
- 11 sites in United States
- Volunteers
- 164 people
- Sponsor
- Mallinckrodt
Constipation Chronic Idiopathic
Vibrant Capsule vs. Placebo for Patient Suffering From Constipation
The objectives are to assess the efficacy and safety of Vibrant capsule administered twice a week
- Trial name
- Capsule (NCT05036369)
- Testing
- Vibrant capsule
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vibrant Ltd.
Constipation
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics (stool frequency, stool consistency, stool ease of passage, stool completeness of evacuation) of MD-1100 acetate administered daily for 14…
- Trial name
- NCT00306748
- Testing
- MD-1100 Acetate
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Constipation
Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation
The purpose of the study is to determine whether prucalopride is safe and effective in patients with chronic idiopathic constipation.
- Trial name
- NCT00596596
- Testing
- prucalopride, 2 mg prucalopride, 4 mg prucalopride
- Volunteers
- 313 people
- Sponsor
- Movetis
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Lubiprostone for Chronic Idiopathic Constipation Treatment
The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02729909
- Testing
- Lubiprostone
- Where
- 10 sites in Mexico
- Volunteers
- 211 people
- Sponsor
- Takeda
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available…
- Trial name
- NCT00511771
- Testing
- Tegaserod
- Sponsor
- Novartis